Metaphore Biotechnologies
Lovisa Afzelius has a diverse work experience in the biotechnology and pharmaceutical industries. Lovisa is currently an Origination Partner at Flagship Pioneering and the Founding CEO & Director of Alltrna. In 2020, they co-founded and served as the CEO of Apriori Bio. In 2021, they co-founded and became the CEO of Metaphore Biotechnologies. Lovisa Afzelius is also a Co-founder & CEO at FL89, starting in 2022. Prior to these roles, they held leadership positions at Elsa Science as a Board Member and Chairman of the Board, Generate Biomedicines, Inc. as the President, Repertoire Immune Medicines as a Senior Vice President, and Pfizer, where they held various senior leadership positions. Lovisa also served as a Board of Directors member at the Swedish American Chamber of Commerce - New England.
Lovisa Afzelius completed their Master of Business Administration (MBA) degree at the MIT Sloan School of Management from 2014 to 2016. Prior to that, from 2001 to 2004, they pursued their doctoral degree in Computational Chemistry at the University of Uppsala. Finally, from 1995 to 2000, Lovisa Afzelius attended the University of Gothenburg, where they obtained their MSc degree.
This person is not in any teams
This person is not in any offices
Metaphore Biotechnologies
Metaphore Biotechnologies is harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. The company’s MIMiC™ platform is a computationally driven bioplatform designing new therapeutics where function, specificity, and selectivity can be optimized. Metaphore is focused on making previously intractable drug targets accessible and unlocking breakthroughs that outperform today’s drugs for maximum patient impact. Metaphore was founded in 2021 in Flagship Labs, a unit of Flagship Pioneering.